Influenza vaccines: Evaluation of the safety profile

Trombetta, Claudia Maria; Gianchecchi, Elena; Montomoli, Emanuele

doi:10.1080/21645515.2017.1423153

Cited by 61 publications

(33 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccine safety profiles were similar in high-risk and healthy subjects, with predictably higher frequencies of mild-to-moderate AEs experienced after aIIV4 administration. 25 …”

Section: Discussionmentioning

confidence: 99%

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial

Esposito¹,

Fling

Chokephaibulkit

et al. 2020

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Vaccination against seasonal influenza is recommended for all children with a history of medical conditions placing them at increased risk of influenza-associated complications. The immunogenicity and efficacy of conventional influenza vaccines among young children are suboptimal; one strategy to enhance these is adjuvantation. We present immunogenicity and safety data for an MF59-adjuvanted quadrivalent influenza vaccine (aIIV4) in healthy children and those at a high risk of influenza-associated complications, based on the results of a recently completed phase III study. Methods: Children 6 months to 5 years of age (N = 10,644) were enrolled. The study was conducted across northern hemisphere seasons 2013–2014 and 2014–2015. Subjects received either aIIV4 or a nonadjuvanted comparator influenza vaccine. Antibody responses were assessed by hemagglutination inhibition assay against vaccine and heterologous strains. Long-term antibody persistence was assessed (ClinicalTrials.gov: NCT01964989). Results: aIIV4 induced significantly higher antibody titers than nonadjuvanted vaccine in high-risk subjects. aIIV4 antibody responses were of similar magnitude in high-risk and healthy subjects. Incidence of solicited local and systemic adverse events (AEs) was slightly higher in aIIV4 than nonadjuvanted vaccinees, in both the healthy and high-risk groups. Incidence of unsolicited AEs, serious AEs and AEs of special interest were similar for adjuvanted and nonadjuvanted vaccinees in the healthy and high-risk groups. Conclusion: aIIV4 was more immunogenic than nonadjuvanted vaccine in both the healthy and high-risk study groups. The reactogenicity and safety profiles of aIIV4 and the nonadjuvanted vaccine were acceptable and similar in 6-month- to 5-year-old high-risk and healthy children.

show abstract

“…Vaccine safety profiles were similar in high-risk and healthy subjects, with predictably higher frequencies of mild-to-moderate AEs experienced after aIIV4 administration. 25 …”

Section: Discussionmentioning

confidence: 99%

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial

Esposito¹,

Fling

Chokephaibulkit

et al. 2020

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…The term SAE indicates “ A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose results in death or is life-threatening” [ 88 ]. SAEs have to be compulsorily notified [ 89 ].…”

Section: A Novel Quadrivalent Inactivated Influenza Vaccine: Vaxigmentioning

confidence: 99%

Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults

et al. 2018

Self Cite

View full text Add to dashboard Cite

Since the mid-1980s, two lineages of influenza B viruses have been distinguished. These can co-circulate, limiting the protection provided by inactivated trivalent influenza vaccines (TIVs). This has prompted efforts to formulate quadrivalent influenza vaccines (QIVs), to enhance protection against circulating influenza B viruses. This review describes the results obtained from seven phase III clinical trials evaluating the immunogenicity, safety, and lot-to-lot consistency of a new quadrivalent split-virion influenza vaccine (Vaxigrip Tetra®) formulated by adding a second B strain to the already licensed TIV. Since Vaxigrip Tetra was developed by means of a manufacturing process strictly related to that used for TIV, the data on the safety profile of TIV are considered supportive of that of Vaxigrip Tetra. The safety and immunogenicity of Vaxigrip Tetra were similar to those of the corresponding licensed TIV. Moreover, the new vaccine elicits a superior immune response towards the additional strain, without affecting immunogenicity towards the other three strains. Vaxigrip Tetra is well tolerated, has aroused no safety concerns, and is recommended for the active immunization of individuals aged ≥6 months. In addition, preliminary data confirm its immunogenicity and safety even in children aged 6–35 months and its immunogenicity in older subjects (aged 66–80 years).

show abstract

“…The other major challenging factor for the development of a vaccine against RNA virus is its ultra-fast mutation rate and critical adverse effects associated with it. For instance, initial trails of the Flu vaccine in 2009 show mild adverse effects like tenderness in muscles, pain at the injection site, headache, malaise, and muscle pain (8). WHO recommended this vaccine for the different flulike syndrome as there are no significant differences in their adverse effects.…”

Section: Introductionmentioning

confidence: 99%

A Review of Current Interventions for COVID-19 Prevention

Pradhan

Biswasroy

Naik

et al. 2020

Archives of Medical Research

298

229

View full text Add to dashboard Cite

The recent outbreak of CoVID-19 is declared as a global public health emergency of international concern by the World Health Organization (WHO). A fresh figure of 2268011 positive cases and 155185 death records (till April 18 th 2020) across the worldwide signify the severity of this viral infection. CoVID-19 infection is a pandemic, surface to surface communicable disease with a case fatality rate of 3.4% as estimated by WHO up to March 3 rd 2020. Unfortunately, the current unavailability of an effective antiviral drug and approved vaccine, worsen the situation more critical. Implementation of an effective preventive measure is the only option left to counteract CoVID-19. Further, a retrospective analysis provides evidence that contemplates the decisive role of preventive measures in controlling severe acute respiratory syndrome (SARS) outbreak in 2003. A statistical surveillance report of WHO reflects, maintaining a coherent infection, prevention and control guideline resulted in a 30% reduction in healthcare-associated infections. The effectiveness of preventive measures completely relies on the strength of surface disinfectants, the composition of hand sanitizer, appropriate material for the manufacture of personal protective equipment (PPE). This review enlightens the various preventive measures such as a suitable selection of surface disinfectants, appropriate hand sanitization, and empowering the PPE that could be a potential intervention to fight against CoVID-19.

show abstract

Influenza vaccines: Evaluation of the safety profile

Cited by 61 publications

References 170 publications

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial

Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults

A Review of Current Interventions for COVID-19 Prevention

Contact Info

Product

Resources

About